Daprodustat is an investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor in development for anaemia due to chronic kidney disease
News
Opdivo plus chemo improves event-free survival in NSCLC patients
Detailed results from the CheckMate-816 trial will be shared at an upcoming medical conference
AZ announces US fast track designation for IL-5 inhibitor Fasenra
Designation granted for the treatment of eosinophilic gastritis with or without eosinophilic gastroenteritis
UK gov’t warns of Christmas COVID restrictions, push for booster vaccines
Around 60% of those eligible have received their booster vaccinations in the UK
Pfizer’s COVID-19 pill cuts hospitalisation/death risk by 89%
The trial evaluated the investigational medicine in non-hospitalised adult patients with COVID-19 who are at high-risk of progressing to severe illness
Novartis’ iptacopan hits endpoints in mid-stage study
Investigational treatment is being evaluated in patients with C3 glomerulopathy
NICE issues draft recommendation for new kidney disease treatment
Forxiga becomes the first new treatment option for CKD patients in nearly 20 years
Researchers find HPV vaccine cuts cervical cancer by 87%
The research paper, published in the Lancet and funded by Cancer Research UK, considered all cervical cancers diagnosed in England among women aged 20-64 between January 2006 and June 2019
UK approval for MSD/Ridgeback’s COVID-19 antiviral med
The antiviral medicine will be marketed with the trademark name Lagevrio in the UK
Guardant Health and Royal Marsden NHS Foundation Trust announce partnership
Partnership will establish an in-house liquid biopsy testing service, using Guardant Health’s proprietary digital sequencing platform
NICE recommends Namuscla for NHS to treat genetic disorder
It is estimated that around 250 people will be eligible to have Namuscla
Novartis signs $1.3bn deal with UK-based Dunad
Dunad will apply its own platform to generate the novel covalent and targeted protein degrading small molecule drugs
ICEBERG study demonstrates improved outcomes of nasal spray for TRD
Back in 2019, esketamine was commercialised as Spravato, described as a “breakthrough” medication used to treat depression
EMA ends rolling review for COVID antibodies
Bamlanivimab and etesevimab are intended for use in COVID patients at high risk of disease progression
First authorisation for Novavax COVID-19 jab announced
Indonesia becomes the first country to authorise the vaccine
